HIV Infections, Hypertension
Conditions
Keywords
HIV, blood pressure, left ventricle, metabolic profile, treatment experienced
Brief summary
Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are associated with an increased risk of cardiovascular disease: a wide range of alterations in lipid and glucose metabolism has been increasingly recognized in HIV patients treated with HAART. Few data are available on the effects of antihypertensive treatment on cardiac morpho-functional characteristics and metabolic parameters in HIV patients. Aim of the study is to assess the effects of chronic therapy with angiotensin receptor blocker(candesartan)or calcium channel blocker (lercanidipine)on metabolic profile and cardiac remodelling in HIV hypertensive patients.
Interventions
DRUGcandesartan
tablet 8-16 mg once daily, one year
DRUGlercanidipine
tablets 10-20 mg once daily, one year
Sponsors
Università degli Studi dell'Insubria
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* HIV infection * office blood pressure \> 140/90 mmHg * no antihypertensive treatment * good quality echocardiogram
Exclusion criteria
* cardiovascular diseases * hypothyroidism * diabetes * secondary hypertension * hepatic and renal failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| morpho-functional left ventricle characteristics | one year |
| metabolic profile | one year |
Secondary
| Measure | Time frame |
|---|---|
| systolic and diastolic blood pressure | one year |
Countries
Italy
Contacts
Primary Contactanna maria grandi, MD
Outcome results
None listed